Notice for bemarituzumab (Amgen Australia Pty Ltd)
Active ingredients
bemarituzumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for injection
Indication
The treatment of gastric cancer
Therapeutic area
Oncology